Trial Profile
Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 02 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 02 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 03 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.